97results about How to "Dose-dependent" patented technology

The invention provides silkworm pupa oil, an extracting method and an application thereof. The silkworm pupa oil consists of the following components with the weight percentage of 0.2 percent of hexadecanoic acid, 1.0 percent of palmitoleic acid, 27.2 percent of oleic acid, 10.7 percent of linoleic acid, 54.6 percent of alpha-linolenic acid and 6.3 percent of other unsaturated acids. The extracting method of the silkworm pupa oil extracts unsaturated fatty acid in the silkworm pupas by a method which combines a microwave extracting technology and urea clathration. The application of the silkworm pupa oil is that the silkworm pupa oil is applied to effectively reducing the blood sugar and the level of diabetic and is especially used for preventing and curing the diabetes. The silkworm pupa oil has the advantages of shortening extracting time, reducing energy consumption, reducing solvent dosage, improving the content of necessary fatty acid and especially the content of the alpha-linolenic acid in the silkworm pupa which benefit human body, reducing the oxidative damage to the unsaturated fatty acid, protecting a double-health structure, economic and simple extracting method, being grasped easily, being convenient for realizing industrialized mass production, the more outstanding pharmacological action of the silkworm pupa oil represented in the aspect of reducing blood sugar, etc.

The invention discloses a series drugs for resisting novel coronavirus SARS-CoV-2 and application thereof. In-vitro cell test results show that compounds disclosed in the invention can significantly inhibit infection of SARS-CoV-2 on normal cells, have an inhibition effect on novel coronavirus SARS-CoV-2 at a cellular level, can significantly reduce the virus titer of novel coronavirus in cells and inhibit proliferation of the novel coronavirus in cells, and has dose dependence. Therefore, the compounds can be used as inhibitors for novel coronavirus SARS-CoV-2, and has the potential of treating COVID-19 pneumonia caused by infection of a human body with the coronavirus SARS-CoV-2 or other diseases caused by infection of animals with the coronavirus SARS-CoV-2.

The present invention discloses application of ganoderic acid T and ganoderic acid Me in preparation of inhibitor of tumor growth or proliferation. The internal and external tests show that ganoderic acid T and ganoderic acid Me have obvious action for inhibiting human tumor cell growth or proliferation, at the same time its toxicity for normal cell is low.

The invention discloses a method for the expression and production of FGF (fibroblast growth factor)-20. By the method of bioinformatics for optimization design, full length FGF-20 nucleotide sequence is synthesized, and is connected with pET series carriers, the expression carrier connection is introduced into proper escherichia coli host cells, a high expression quantity and stable inheritance engineering strain is obtained through screening, a high density fermentation method, an inclusion body expression FGF-20 purification method and a corresponding quality detection method are established, and mass production of rhFGF-20 is possible. On the basis, clinical application of the FGF-20 in tissue repair and degenerative diseases of the nervous system and effect of the FGF-20 in occurrence, development and migration of tumors can be further explored.

The invention discloses application of a gallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The gallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine. The formula (I) is as shown in the specification.

The invention relates to application of auranofin to preparation of anti-angiogenic medicines. So far, there is no report on anti-angiogenic activity of auranofin. The invention provides application of auranofin to preparation of anti-angiogenic medicines. A zebra fish angiogenic model is used for verification, and auranofin can substantially inhibit angiogenesis of the zebra fish. Accordingly, auranofin can be used for preparation of anti-angiogenic medicines.

An application of L-serine in preparing the slow-release or release controllable medicines in the form of solid, liquid, or spray for treating cerebral ischemia is disclosed.

The invention belongs to the field of biomedical engineering, and particularly relates to a method for preparing a specific magnetic Endoglin aptamer imaging probe system (mEND-Fe3O4@CMCS). Magnetic Fe3O4 nano-particles are prepared with the hydrothermal method, magnetic chitosan nano-particles Fe3O4@CMCS are prepared with glutaraldehyde as the cross-linking agent by means of the emulsification and cross-linking method, and then the surface of Fe3O4@CMCS is modified with an Endoglin aptamer by means of the cross-linking action of Sulfo-SMCC, so that the magnetic Endoglin aptamer imaging probe mEND-Fe3O4@CMCS is obtained. The magnetic Endoglin aptamer imaging probe mEND-Fe3O4@CMCS prepared with the method can effectively target mouse tumor angiogenesis endothelial cell (mTEC) surface CD105 molecules, has hepatic transplantable tumor mouse MRI imaging capability, and has the advantages that sensitivity is high, T2 imaging efficiency is high, the MRI contrast effect is good, toxicity is low, the relaxation rate is high, biocompatibility is high, and liver and spleen targeting can be realized.

The invention discloses anti-inflammatory or analgesic activity of novel C20 ditepenoid alkaloid compounds (I) and (II) which can be dose-dependently achieved under safe dosage. Animal experiment results prove that the compounds 3 have a remarkable effect of inhibiting ear swelling of mice and an analgesic effect, and is expected to become a medicine for treating diseases related to inflammation and/or pains.

The invention provides a preparation method of traditional Chinese medicine granules, and the traditional Chinese medicine granules prepared by the same. The traditional Chinese medicine granules comprise the following crude drugs in parts by weight: 30-60 parts of astragalus membranaceus, 9-15 parts of glossy privet fruit, 9-30 parts of motherwort, 3-10 parts of smoked plum, 2-9 parts of coptis chinensis, 1-5 parts of cinnamon and 3-9 parts of butterflybush flower. The preparation method comprises the following steps: extracting essential oil from cinnamon, and covering the essential oil by beta-cyclodextrin; extracting astragalus membranaceus, glossy privet fruit and butterflybush flower by use of an ethanol solution I; extracting residues of the smoked plum and the cinnamon, and residues of the astragalus membranaceus, the glossy privet fruit and the butterflybush flower by water; extracting the motherwort and the coptis chinensis by use of an ethanol solution II; mixing each part of extracted extractum; adding pharmaceutical acceptable auxiliary materials, pelletizing, and adding an essential oil inclusion compound; and evenly mixing the materials, so as to obtain the traditional Chinese medicine granules. Compared with the prior art, the preparation method has the advantage of obviously improving the active substance content and pharmacologic action of the traditional Chinese medicine granules.

The invention discloses an application of quercitrin in preparation of a human gamma delta T cell proliferator, and relates to the technical field of medicines. Quercitrin can remarkably promote proliferation of human gamma delta T cells and promote expression of perforin and granzyme B, so that the quercitrin is of certain dose dependency. The gamma delta T cell treated by the quercitrin can promote expression of p-ERK (Extracellular signal-Regulated Kinase)1/2 and p-Akt in active form and promote expression of an anti-apoptoasis protein Bcl-2, so that the gamma delta T cell is of certain dose dependency. The invention discovers the novel medical use of quercitrin and provides experimental references to development of tumor immunotherapy medicines.

The invention provides a traditional Chinese medicine capsule for treating diabetic retinopathy and an application of the traditional Chinese medicine capsule for treating diabetic retinopathy. The traditional Chinese medicine comprises the following raw materials in parts by weight: 30 to 60 parts of astragalus membranaceus, 9 to 15 parts of glossy privet fruit, 9 to 30 parts of leonurus, 3 to 10 parts of smoked plum, 2 to 9 parts of coptis chinensis, 1 to 5 parts of cortex cinnamomi and 3 to 9 parts of butterflybush flower. The preparation method of the capsule comprises the following steps: extracting a volatile oil from the cortex cinnamomi and enveloping the volatile oil with Beta-cyclodextrin; extracting medicinal residues of the cortex cinnamomi and the rest of medicinal materials by virtue of an ethanol solution with the volume percentage concentration of 30% to 80%; refining an extract with macroporous adsorption resin and drying so as to obtain dry extract powder; adding a volatile oil clathrate into the dry extract powder, evenly mixing, adding pharmaceutically acceptable auxiliary materials and filling into a capsule so as to obtain the traditional Chinese medicine capsule. Compared with the prior art, the content of active substances in the traditional Chinese medicine capsule provided by the invention is obviously improved, so that the obvious pharmacologic action of the traditional Chinese medicine capsule provided by the invention is achieved.

The invention discloses antibacterial peptide dimer analogues containing D type amino acids. The dimer analogues are prepared by respectively performing N-terminal side chain polymerization on D type amino acid-containing precursor peptides of a naturally antibacterial peptide Anoplin. According to determination of the lowest minimum inhibitory concentration of common standard microorganisms, a biofilm formation test is inhibited. An enzymatic stability test shows that the antibacterial activities of the antibacterial peptide dimer analogues containing D type amino acids synthesized according to the invention are enhanced by 4-16 times compared with those of parent peptides, and the dimer analogues have strong abilities of inhibiting bacterial biofilm formation. In addition, the stabilities of the antibacterial peptide dimer analogues containing D type amino acids synthesized according to the invention are obviously improved. Compared with the parent peptide Anoplin, the tolerance to trypsin enzymolysis is improved by 104-105 times, and the tolerance to chymotrypsin is improved by 102 times. Therefore, the antibacterial peptide dimer analogues containing D type amino acids have excellent application prospects in preparation of long-lasting clinical antibacterial drugs.

The invention discloses a polypeptide WA8 for inhibiting type-2 shiga toxin activity and a coding gene and application thereof. The polypeptide provided by the invention is named as WA8 (also named P8), and the amino acid sequence of the polypeptide is expressed as a sequence 2 in a sequence table. The polypeptide P8 can be prepared into a medicament for preventing and/or treating diseases caused by type-2 shiga toxin or pathogenic bacteria which can generate the type-2 shiga toxin.

The invention discloses application of a berberine and doxorubicine mixed preparation in preparation of a medicament against doxorubicine cardiac dysfunction or tumor. The molar concentration ratio of the berberine to the doxorubicine in the medicament is (0.625-4): 1, and the optimal ratio is 1:1. The medicament is an oral preparation or an injection preparation. The combined use of the berberine and the doxorubicine can lighten myocardial damage caused by the doxorubicine, also can play a role in inhibiting myocardial apoptosis caused by the doxorubicine, and does not weaken, even enhance the anti-tumor effect of the doxorubicine at the same time.

The invention discloses a medicinal composition for inducing stem cells to differentiate into cartilage and an application of the medicinal composition. The medicinal composition comprises puerarin and tetrandrine. The invention also discloses an application of the medicinal composition in preparing medicaments or health-care products for inducing bone marrow mesenchymal stem cells (BMSCs) to differentiate into cartilage cells and an application of the medicinal composition in medicaments for treating osteoarthritis. According to the invention, puerarin and tetrandrine are proportioned to replace cytokines or hormones to jointly induce BMSCs to differentiate to cartilage, so that the defect that medicines cannot be widely applied to clinical practice due to high price and safety problems is overcome; and the puerarin and the tetrandrine are proportioned to improve the success rate of stem cell transplantation, reduce rejection reactions and reduce the risk of stem cells differentiate to tumors. The medicine composition provided by the invention has obvious effects in inducing BMSCs to differentiate into cartilage cells, has dose dependence, is suitable for popularization and application, and provides a new BMSCs induction medicine source for treating osteoarthritis diseases.

The invention relates to fusion protein with double functions of inhibiting revascularization of a tumor microenvironment and activating adaptive immune response, and a gene and application thereof. The invention discloses a group of recombinant protein with Tumstatin and CD137L double functions, and is characterized in that the protein is formed by fusing Tumstatin active segment amino acid sequence (one of SEQ ID NO. 52 to SEQ ID NO. 55) and CD137L extracellular domain protein segment amino acid sequence (one of SEQ ID NO. 64 to SEQ ID NO. 66) through flexible connecting peptide. The protein and the protein coding gene can be applied to research and application of tumor angiogenesis inhibitors, various oncology related diseases and body immunity adjusting medicines.

The invention belongs to the technical field of medicines and particularly relates to application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses. The average molecular mass of the eucheuma gelatinae polysaccharide ranges from 1,000 to 100,000. Pharmacological experiments show that the eucheuma gelatinae polysaccharide has the function of independently inhibiting respiratory viruses which mainly include respiratory syncytial viruses, Coxsackie viruses and influenza viruses. The inventor uses ribavirin together with eucheuma gelatinae polysaccharide and heparin together with eucheuma gelatinae polysaccharide to inhibit respiratory viruses, and results shown that ribavirin and eucheuma gelatinae polysaccharide or heparin and eucheuma gelatinae polysaccharide can be used together to achieve an unexpected treatment effect synergistically. Antiviral medicines such as tablets, capsules, granules, sustained-release tablets and sprays can be prepared from eucheuma gelatinae polysaccharide. The eucheuma gelatinae polysaccharide has strong respiratory virus inhibiting activity, has low toxicity on a host cell, can be used for preparing medicines with high antiviral activity and low toxicity and has broad application prospect.

The invention discloses application of ethyl ammonium sulfate in preparing a medicine for treating inflammation, fever, diarrhea and cough and being used as an NF-kB inhibitor drug and a preparation method and composition of the ethyl ammonium sulfate.